Allo-SCT can result in long-term remission in patients with multiple myeloma (MM), although its overall role in disease management remains controversial. We evaluated lenalidomide monotherapy response and tolerability among 18 patients with MM who progressed or relapsed after Allo-SCT, who were enrolled a median of 12 months (range 3-104) following transplant. Treatment duration of lenalidomide was 8 months (range 1-57). Ten patients required dose reductions from 25 to 5-20 mg at a median of three cycles (range 1-12): eight for neutropenia, one for thrombocytopenia and one for myalgias and weakness. Serious adverse events (N ¼ 5) included H1N1 influenza (2), bacterial pneumonia (2) and fever, myalgia and hypoxia. Two patients died at 3 and 5 months of gastrointestinal or hepatic GVHD occurring within 1 month of dosing. Responses included complete response (CR) (5), very good partial response (2), partial response (PR) (3), minimal response (1) and stable disease (2) for an overall response rate (XPR) of 56%. Ten patients discontinued therapy for progressive disease (PD) at a median of 8.5 (1-43) months. Six patients died from PD. Five patients remained on therapy at 39 months (range 14-57), with four in CR. Lenalidomide for relapse of MM after Allo-SCT can result in extended disease control (412 months) in 50% of patients.
INTRODUCTION
There has been enormous progress in the treatment of multiple myeloma (MM) owing to the development of new drugs and the widespread use of high-dose therapy and Auto-SCT. 1, 2 Median OS has improved from 3 to 5 years and patients diagnosed before the age of 50 years, without high risk features, may expect to live for more than 10 years. 2, 3 Despite these improvements, MM remains incurable for the large majority of patients who will eventually die of recurrent disease. Myeloablative Allo-SCT was the first therapy demonstrated to produce durable, long-term remission in some patients with MM. High rates of transplant-related mortality, however, have limited its use to relatively few, younger patients. [4] [5] [6] The development of non-myeloablative, reduced-intensity conditioning regimens with improved early mortality led to wider application and several trials comparing Auto-SCT with reduced-intensity Allo-SCT. These trials have produced inconsistent results, with several trials demonstrating improved OS for Allo-SCT, whereas others have shown equivalent outcomes. [7] [8] [9] [10] [11] [12] Thus, the role of Allo-SCT in the overall management of MM remains controversial.
Few studies have examined treatment outcomes for patients who receive Allo-SCT and develop recurrent disease. The most widely reported treatment, DLI, results in complete response rates of B20% in which remissions may be durable in selected patients, but with an increased risk of GVHD. [12] [13] [14] Lenalidomide is a second-generation 'immunomodulatory' drug with substantial activity in newly diagnosed and relapsed MM. In the relapsed setting, response rates to monotherapy are B25%.
15 Allo-SCT results in an entirely new immune effector mechanism for graft recipients and has the potential for improved response to immunomodulatory agents. One report using lenalidomide as maintenance therapy after Allo-SCT observed an intolerable rate of GVHD and it was concluded that the drug could not be used in this setting. 16 Other reports have demonstrated its activity in patients with MM who relapse after Allo-SCT. 17, 18 To address this question, we designed a prospective trial to examine the activity and toxicity of lenalidomide monotherapy in patients in the relapsed setting after Allo-SCT.
MATERIALS AND METHODS
This prospective study was initiated in March 2008, with the final patient enrolled in December 2011. The trial enrolled patients with MM who had received a prior Allo-SCT, either ablative or non-myeloablative, from either a related or an unrelated donor, and who subsequently experienced disease progression or relapse at any time following transplant. Eligibility included progression according to the European Group for Bone Marrow Transplantation Criteria, which included a 25% increase in monoclonal protein or a 50% increase in urinary protein, new or increased bone lesions or hypercalcemia. 19 Patients must have discontinued all cancer-related therapy, except for corticosteroids or immunosuppressive therapy for GVHD at least 4 weeks before beginning lenalidomide. Patients had to have an Eastern Cooperative Oncology Group (ECOG) status p2 and meet minimum organ function requirements, including blood counts with absolute neutrophils 1.5 Â 10 9 /L and platelets 50 Â 10 8 /L, creatinine p2 mg/dL, bilirubin p1.5 mg/dL and serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) p2 times the upper limit of normal. Female participants could not be pregnant, and patients were required to comply with the RevASSIST program. Exclusions included prior malignancy within 5 years of diagnosis, acute GVHD grades 3-4, known hypersensitivity to thalidomide or lenalidomide and known positivity to HIV or to hepatitis viruses.
The trial's primary objective was to determine the overall response rate, with secondary objectives of determining safety, PFS and OS.
The starting dose of lenalidomide monotherapy was 25 mg orally on days 1-21 every 28 days. Dose reductions at 5 mg increments were allowed after cycle 1 for neutropenia, thrombocytopenia or non-hematologic toxicities. Patients received aspirin 81 mg or 325 mg for thromboprophylaxis. The trial was designed to enroll 18 patients.
RESULTS
Eighteen patients were enrolled in the trial during the 3-year 9-month interval. Their characteristics are shown in Table 1 . Patients were of a median age of 54.5 years (range 33-66). They had received a median of 2.5 lines of prior therapy (range 1-6). Sixteen patients had received a prior autologous transplant as part of a tandem autologous-allogeneic transplant approach. Five patients had relapsed after a prior autologous transplant and received a second autologous transplant as part of the tandem approach. One patient had undergone two non-ablative transplants without a prior autograft, whereas one patient had received only a single ablative allograft using a BU-melphalan preparative regimen. All patients received mobilized PBSCs from either matched siblings (N ¼ 11), matched unrelated donors (N ¼ 6) or a C locus, mismatched unrelated donor (N ¼ 1). Six donors were sex mismatched with their recipient. Eight patients developed acute GVHD of grade 2. Eight patients developed chronic GVHD requiring treatment. Fourteen patients responded after an allogeneic transplant: 10 showed complete response and four showed partial response. Eight patients had received lenalidomide before their allogeneic transplant. Disease relapse, progression and trial enrollment occurred at 2-101 months (median 12 months) following an allogeneic transplant. Four patients relapsed after receiving two or more doses of bortezomib 1.3 mg/m 2 given every other week as maintenance after the Allo-SCT. The duration of lenalidomide therapy was a median of 12 months (range 0.5-57 þ months). Table 2 shows that responses were complete (n ¼ 5), very good (n ¼ 2) or partial (n ¼ 3) for an overall response rate of 56%. Two additional patients showed minimal response or had stable disease.
Common adverse events, grades 1-2, were constipation (28%), diarrhea (17%), fatigue (17%), myalgia (17%), nausea (11%), neuropathy (11%), rash (11%) and thrombocytopenia (11%). Grade 3 adverse events were pneumonia (17%), H1N1 influenza (11%), and fever, hypoxia, neuropathy (6%) and myalgias (6%). Eight patients required dose reductions to 20-10 mg for grade 3 neutropenia. One patient required dose reduction to 15 mg for neuropathy.
Three patients received steroids during lenalidomide. Two were on a prednisone taper during the first 2 months of therapy. A third patient had dexamethasone 20 mg added for rising monoclonal protein levels after 1 year of monotherapy and had stable disease for another year before disease progression. Ten patients discontinued therapy owing to progressive disease after a median of 8.5 months (range 1.2-43) of therapy. One patient discontinued therapy after 1.3 months owing to toxicity characterized as myalgias, weakness and fever, despite a dose reduction to 10 mg. Two patients received only 14 and 19 days of lenalidomide at 25 mg/day; they discontinued owing to the development of GVHD, one in the setting of a rapid taper of immunosuppression. In retrospect, one of these two patients had normal liver function tests at the time of trial registration but abnormal tests 10 days later, immediately before the start of lenalidomide. Both patients died owing to complications of GVHD, 3 and 5 months following trial initiation. Eight patients died 2-44 months after beginning lenalidomide, six because of disease progression and two because of GVHD. Ten patients are still alive at a median of 35 months (range 14-57) with five still on therapy at a median of 39 months (range 14-57).
DISCUSSION
This prospective study confirms the efficacy of lenalidomide monotherapy in 18 patients who experienced disease progression after undergoing an Allo-SCT. Overall lenalidomide was well tolerated with only three patients discontinuing therapy for toxicity-or GVHD-related issues. About one-half of patients required dose reductions of lenalidomide, primarily for neutropenia and one patient for neuropathy, which occurred 4-24 months after the start of therapy.
Overall response rates in this heavily pretreated population were encouraging at 56%. This is superior to the historical 26% response rate reported for lenalidomide monotherapy among patients who had not undergone an allogeneic transplant. 15 Ten patients experienced disease control for at least 1 year (range 12-57 þ months). Steroids were used in three patients in our study: two were completing a prednisone taper (on 20 mg daily or alternate day prednisone) and one had dexamethasone added for a rising monoclonal protein level after 1 year of monotherapy. The improved response rate and extended disease control suggest that lenalidomide may augment the donor immune response against myeloma in the post-transplant setting. An increase in the frequency of CD4 þ Foxp3 þ T cells has been demonstrated in response to lenalidomide administration. 17 Other groups have observed an increase in the anti-myeloma activity of NK cells among patients on lenalidomide. 20 After allogeneic transplant, lenalidomide has been used both as maintenance therapy and as a form of consolidation to improve responses in combination with DLI. 21 Unlike the HOVON group, which reported a 47% incidence of acute GVHD with a 10 mg dose, only two patients developed GVHD in our study. 16 This reduced incidence could be related to the timing of administration after the transplant: 12 months in our trial versus 3 months in the trial using it for maintenance. Another trial of lenalidomide maintenance in high-risk patients started between days 100 and 180 after allogeneic transplant observed a 38% incidence of GVHD, which led to discontinuance in 29% of patients. 20 Lenalidomide 10 mg has also been given with DLI beyond day 100, after all immunosuppression had been completed, without an apparent increase in GVHD. 21 Thus, the timing of lenalidomide administration after allografting is likely an important factor related to the risk of exacerbating GVHD. One study preemptively utilized a combination of 1-3 DLIs plus either thalidomide, lenalidomide or bortezomib in patients with myeloma who had passed 100 days after an Allo-SCT and had not achieved a complete response. They observed a 59% rate of complete response without excessive GVHD. 22 One report on 16 patients who relapsed after allogeneic transplant and were given lenalidomide with dexamethasone (n ¼ 8) found an 87% response rate; however, the response rate was only 46% with lenalidomide monotherapy. 17 Some of these patients were given DLI in close proximity to lenalidomide. GVHD grades 2-4 occurred in 5/16 patients. A retrospective study from a French consortium that reported on 52 patients who received lenalidomide 25 mg þ dexamethasone (77%) started a median of 24 months after transplant for relapsed disease found an 83% response rate.
18 About 1/3 of patients experienced an exacerbation of GVHD. GVHD was more frequent in patients receiving lenalidomide as first-line salvage and in patients who had recently discontinued immunosuppression. In our own study one of the two cases of ultimately fatal GVHD occurred in the setting of lenalidomide therapy initiated while immunosuppression was rapidly tapered. Taken together, these studies suggest that lenalidomide is better tolerated beyond the 3-month period from an allogeneic transplant and when immunosuppression is completed without the development of GVHD.
In summary, our prospective study suggests that lenalidomide monotherapy can be given safely to most patients who relapse after Allo-SCT for myeloma. Furthermore, lenalidomide appears to be highly effective in this setting, resulting in a significant response rate and prolonged disease control in some patients.
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